Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Chakravarti A, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17. doi: 10.1016/j.ijrobp.2004.09.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890569
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
Khor LY, Desilvio M, Li R, McDonnell TJ, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A. Khor LY, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):25-30. doi: 10.1016/j.ijrobp.2006.03.056. Epub 2006 Jul 11. Int J Radiat Oncol Biol Phys. 2006. PMID: 16814949 Free PMC article.
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Feng M, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1417-23. doi: 10.1016/j.ijrobp.2007.01.049. Epub 2007 Apr 6. Int J Radiat Oncol Biol Phys. 2007. PMID: 17418972
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
Roach M 3rd, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. Roach M 3rd, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):79-87. doi: 10.1016/j.ijrobp.2007.03.008. Epub 2007 May 10. Int J Radiat Oncol Biol Phys. 2007. PMID: 17498886 Clinical Trial.
ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
Michalski JM, Roach M 3rd, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. Michalski JM, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):667-72. doi: 10.1016/j.ijrobp.2008.12.073. Epub 2009 Apr 20. Int J Radiat Oncol Biol Phys. 2009. PMID: 19386445 Review. No abstract available.
967 results